LABORATORIO FARMAC.ERFO (RK7) - Total Liabilities
Based on the latest financial reports, LABORATORIO FARMAC.ERFO (RK7) has total liabilities worth €2.98 Million EUR (≈ $3.48 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RK7 cash generation efficiency to assess how effectively this company generates cash.
LABORATORIO FARMAC.ERFO - Total Liabilities Trend (2021–2023)
This chart illustrates how LABORATORIO FARMAC.ERFO's total liabilities have evolved over time, based on quarterly financial data. See LABORATORIO FARMAC.ERFO net assets for net asset value and shareholders' equity analysis.
LABORATORIO FARMAC.ERFO Competitors by Total Liabilities
The table below lists competitors of LABORATORIO FARMAC.ERFO ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fibon Bhd
KLSE:0149
|
Malaysia | RM4.62 Million |
|
Neola Medical AB
ST:NEOLA
|
Sweden | Skr3.00 Million |
|
Prismaflex Intl
PA:ALPRI
|
France | €24.84 Million |
|
Arbor Metals Corp
V:ABR
|
Canada | CA$215.88K |
|
AUX Resources Corporation
V:AUX
|
Canada | CA$649.44K |
|
Zelan Bhd
KLSE:2283
|
Malaysia | RM540.59 Million |
|
Golden Pharos Bhd
KLSE:5649
|
Malaysia | RM31.83 Million |
Liability Composition Analysis (2021–2023)
This chart breaks down LABORATORIO FARMAC.ERFO's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LABORATORIO FARMAC.ERFO (RK7) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LABORATORIO FARMAC.ERFO's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LABORATORIO FARMAC.ERFO (2021–2023)
The table below shows the annual total liabilities of LABORATORIO FARMAC.ERFO from 2021 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €2.26 Million ≈ $2.65 Million |
-78.50% |
| 2022-12-31 | €10.53 Million ≈ $12.32 Million |
+377.53% |
| 2021-12-31 | €2.21 Million ≈ $2.58 Million |
-- |
About LABORATORIO FARMAC.ERFO
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and pack… Read more